The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer
| ISRCTN | ISRCTN73852054 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN73852054 |
| Protocol serial number | 8166 |
| Sponsor | University of Liverpool |
| Funder | National Institute for Health Research |
- Submission date
- 08/01/2015
- Registration date
- 09/01/2015
- Last edited
- 24/05/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Contact information
Scientific
University of Liverpool
Cancer Research UK Liverpool Cancer Trials Unit
200 London Road
Liverpool
L3 9TA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Non-randomised; Interventional |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer |
| Study acronym | PET-PANC |
| Study objectives | The diagnosis of pancreatic cancer has improved with the use of multidetector CT, EUS, ERCP and additional use of MRI. There are, however, up to 10-20% of patients in whom an accurate diagnosis is difficult. This proportion is increasing due in part to larger numbers of asymptomatic patients undergoing cross sectional imaging. Invasive methods of diagnosis such as EUS +/- FNA can add to the accuracy of multidetector CT but may require an in-patient stay and have a recognised complication rate (1-2%). Currently patients with chronic pancreatitis, autoimmune pancreatitis, cystic lesions, small tumours <2cm, a bulky or diffusely enlarged pancreas on CT, a dilated pancreatic duct and no mass on CT, small volume metastatic disease and suspected recurrent disease (with no mass on CT) following resection are the most challenging patients to diagnose. A major goal of accurate diagnosis and staging is to avoid major pancreatic resection in patients who will not benefit. The use of a functional imaging technique such as PET/CT may add to staging of pancreatic cancer by diagnosing small volume metastatic disease and differentiate between benign and malignant lesions. Earlier diagnosis of pancreatic cancer will lead to a better prognosis for patients and PET/CT may be able to identify small volume disease or cancer arising in patients with chronic pancreatitis. There have been a number of studies to address diagnostic accuracy of PET/CT and two have looked at the issue of changes in management due to PET/CT. The main drawbacks of previous PET/CT studies tend to be that these are single centre studies with small numbers of patients and difficulties in standardising PET/CT protocol in pancreatic cancer. This prospective multicentre study aims to address these issues in a large group of patients to identify whether there is a role for PET/CT in addition to standard diagnostic work up in pancreatic cancer. |
| Ethics approval(s) | NRES Committee North West - GM East (Cheshire), 18/03/2010, ref: 10/H1017/8 |
| Health condition(s) or problem(s) studied | Topic: Cancer, Surgery; Subtopic: Upper Gastro-Intestinal Cancer, Surgery; Disease: Pancreas |
| Intervention | Combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnostic work up of patients with suspected pancreatic malignancy; Follow up length: 12 month(s). |
| Intervention type | Procedure/Surgery |
| Primary outcome measure(s) |
The incremental diagnostic accuracy and impact of PET/CT to standard diagnostic work up; Timepoint(s): Outcome time point will be assessed after 12 Months of follow up |
| Key secondary outcome measure(s) |
1. Determine cost effectiveness of addition of PET/CT in diagnosis, staging and management.; Timepoint(s): After 12 months follow up |
| Completion date | 26/04/2013 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 600 |
| Total final enrolment | 589 |
| Key inclusion criteria | 1. Patients with suspected pancreatic malignancy as defined by one or more of: 1.1. Focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct (+/- metastases) detected on Multidetector CT scan (+/- MRI/EUS/USS) 1.2. Jaundice due to distal obstruction of the common bile duct or ampulla (not due to calculi) defined as serum bilirubin. 35 µmol/l 1.3. Serum CA19.9 value above 37KU/l 2. Able to attend for PET/CT scan 3. Able to undergo Multidetector CT scan 4. Able to attend for up to 12 months follow-up 5. Fully informed written consent given 6. Gender: Male & Female 7. Lower Age Limit 18 years |
| Key exclusion criteria | 1. Patients younger than 18 years 2. Pregnancy 3. Patients with poorly controlled diabetes |
| Date of first enrolment | 06/01/2011 |
| Date of final enrolment | 26/04/2013 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
200 London Road
Liverpool
L3 9TA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/02/2018 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Plain English results | No | Yes |
Editorial Notes
24/05/2019: The following changes were made to the trial record:
1. Added CRUK link to results (plain English).
2. The total final enrolment was added.
06/06/2017: No publications found, verifying study status with principal investigator.
